Aims: Develop a population pharmacokinetics model of tacrolimus in organ transplant recipients receiving twice-daily, immediate-release (IR-T; Prograf) and/or once-daily, prolonged-release (PR-T; Advagraf or Astagraf XL) tacrolimus.
tions, 1 and is highly bound to plasma proteins (approximately 99%), predominantly serum albumin (ALB). 1, 2, 4 Metabolism of systemically available tacrolimus occurs in the liver, primarily by cytochrome P450 3A4 (CYP3A4) and CYP3A5, with predominantly faecal elimination. 2, 5 However, there is also evidence of presystemic gastrointestinal metabolism in the intestinal wall by CYP3A4 and CYP3A5, which reduces the oral bioavailability of tacrolimus. 2, 5 After conversion from immediate-to prolonged-release tacrolimus, mean systemic exposure to tacrolimus (area under the concentration-time curve [AUC] ) with the prolonged-release formulation is approximately 10% lower than the immediate-release formulation at equivalent doses. [6] [7] [8] However, following dose adjustment, exposure is similar at steady state. [9] [10] [11] Tacrolimus administration is complicated by a narrow therapeutic range, and inter-and intrapatient pharmacokinetic (PK) variability. 12 Tacrolimus trough concentrations are monitored to guide dose adjustment, as trough concentration is highly correlated with tacrolimus AUC and subsequently clinical outcomes. 13, 14 The relationship between tacrolimus trough concentrations and AUC is similar between prolonged-and immediate-release tacrolimus in both liver and kidney transplant patients; 15, 16 therefore the same therapeutic drug monitoring approach can be used with both formulations. Tacrolimus whole-blood trough concentrations are generally maintained within the range of 5-20 ng/mL. 17 Several studies have characterized the PK of immediate-release tacrolimus; [18] [19] [20] [21] however, there are few population PK studies characterizing the PK of both immediate-and prolonged-release formulations. 22 This modelling study was undertaken to characterize the population PK of immediate-and prolonged-release tacrolimus in liver, kidney and heart transplant recipients, as well as identify the demographic and covariate factors that have a significant influence on tacrolimus PK.
| METHODS

| Patients and studies
Data were obtained for liver, kidney and heart transplant recipients from 8 Phase II studies with immediate-release tacrolimus (Prograf, Astellas Pharma Ltd, Chertsey, UK) and prolonged-release tacrolimus (Advagraf or Astagraf XL, Astellas Pharma Europe BV, The Netherlands) 11, 15, [23] [24] [25] [26] [27] [28] (Table 1 ). The data presented here were derived from the internal databases of each Phase II study; 6 studies assessed tacrolimus PK in stable transplant recipients converted from immediate-to prolonged-release tacrolimus. 15, [23] [24] [25] [26] [27] Of these, 3 studies assessed adult kidney transplant recipients (02-0-131, FG-506E-12-02, and FJ-506E-KT01), 15, 23, 24 1 assessed adult liver recipients (02-0-152), 25 1 assessed paediatric (mean age 9 years) liver recipients (03-0-160) 27 and 1 assessed adult heart recipients (FG-506-15-02). 26 What is already known about this subject
• Tacrolimus is a mainstay of immunosuppressive therapy after solid-organ transplantation.
• Tacrolimus is available as twice-daily, immediate-release (IR-T) and once-daily, prolonged-release (PR-T)
formulations.
• Tacrolimus has a narrow therapeutic range, with target whole blood trough concentrations of 5-20 ng/mL.
• Tacrolimus trough concentrations are highly correlated with drug exposure and, consequently, with clinical transplant outcomes.
• Few population pharmacokinetics studies have characterized the pharmacokinetics of both immediateand prolonged-release tacrolimus.
What this study adds
• Although tacrolimus absorption rates differed between the immediate-and prolonged-release formulations, interpatient variability in tacrolimus trough concentrations was similar, as was relative bioavailability.
• Racial differences in relative bioavailability were noted (Asians>Whites>Blacks), independent of tacrolimus formulation.
• The results support a 1 mg:1 mg conversion factor for switching patients from immediate-release tacrolimus (Prograf) to prolonged-release tacrolimus (Advagraf or Astagraf XL) in clinical practice.
The other 2 studies compared the PK profile of immediate-and prolonged-release tacrolimus in de novo kidney or liver transplant recipients (FG-506E-12-01 and FG-506-11-01, respectively). 11, 28 Full details of the methodology used in these studies have been reported previously. 11, 15, [23] [24] [25] [26] [27] [28] The study protocols were reviewed and approved by the institutional review board or independent ethics committee of participating institutions, and the studies were conducted in accordance with Good At each PK sampling time point, ≥1 mL of whole blood was collected, and samples frozen at −20°C until analysis. Concentrations of tacrolimus were determined in whole blood (ethylenediaminetetraacetic acid anticoagulant) using high-performance liquid chromatography (LC) with tandem mass spectrometry (MS/MS), with the exception of study FJ-506E-KT01, which utilized an immunoassay. Briefly, internal standard (FR900520) and tacrolimus were extracted from whole blood using protein precipitation followed by solid phase extraction.
Compounds of interest were eluted from the solid phase cartridge with methanol and then dried under a stream of nitrogen (40°C).
The residue was reconstituted with 50:50 (v/v) acetonitrile:water and injected onto the LC/MS/MS system, where separation occurred on a reversed phase high-performance LC column, and was detected with positive electrospray ionization MS/MS. This method was validated for tacrolimus determination in whole blood. Peak area ratios (compound/internal standard) were fitted to a weighted 1/concentration least squares linear regression analysis to calculate the line of best fit from the data. The equations of the calibration curves were then used to calculate the concentrations of tacrolimus in the whole blood samples from their measured peak area ratios.
The lower limit of quantitation was 0.1 ng/mL. employed for all model runs. The NONMEM code for the final PK model is shown in Supporting information Appendix A.
| Base model development
Initially, exploratory data analyses of individual whole-blood tacrolimus concentrations were constructed by study and formulation to qualitatively explore the suitability of different base PK models.
Zero-order absorption and 1-and 2-compartmental models with different absorption assumptions were tested. The interpatient variability and necessary interoccasion variability were modelled as a lognormal distribution. Residual variability was assessed for different assays, using residual error models, including additive, proportional, and combined (i.e. additive and proportional) models, and a residual additive error model with log-transformed tacrolimus concentration data.
Model development and selection were driven by the data and were based on goodness-of-fit indicators. 31 These included compari- 
| Model evaluation
The final full covariate model was evaluated using study-stratified non-parametric bootstrap and prediction-corrected visual predictive checks (pcVPCs). 32, 33 For the non-parametric bootstrap procedure, 1000 replicate bootstrap data sets were obtained by random resampling using the patient as the sampling unit, with replacement from the original data set, and were fitted with the same model to obtain parameter estimates for each replicate. There were 491 runs with minimization terminated and 8 runs with estimates near a boundary, which were skipped. Empirical 95% confidence intervals (CIs) were constructed by obtaining the 2. 
| RESULTS
Overall, 23,176 tacrolimus concentration records were obtained from 408 patients. The baseline characteristics for patients in the final PK data set are summarized in Table 2 . The study included 276 males and 132 females with a median (range) age of 48 years (5-71 years;
17 patients were paediatric) and body weight of 74 kg (18.5-148.5 kg). White (n = 340), Black (n = 24) or Asian (n = 44) were the only self-reported races in the data set.
| Base model
After testing the performance of different structural models, a 2-compartment disposition model with first-order elimination, firstorder absorption and an absorption lag time provided the best fit for ) and F1 (exp 1.04 ) would increase by about 2.8-fold. V c of tacrolimus in females was 55% less than in males.
The inclusion of covariate effects on tacrolimus PK all resulted in statistically significant decreases in OFV compared with the base model (p < 0.001). The type of organ transplanted (kidney vs liver vs heart) had no significant effect on principal PK parameters. As only 4.2% of the studied population were paediatric, there was insufficient power to evaluate the impact of population (adult vs paediatric) on tacrolimus PK. The final population PK model was described by the following equations: All parameter estimates were identified with good precision, as standard errors of the parameter estimates were ≤50% of the esti- 
| Model evaluation
The median values of parameters and 95% CIs obtained from the converged bootstrap runs for tacrolimus are presented in Table 3 . The median values of parameters were in close agreement with the population estimates in the final models, suggesting that the NONMEM parameter estimates of the model were unbiased.
Results from the dose-normalized pcVPC analysis with the final parameter estimates in the tacrolimus PK model are shown in Figure 2 . The pcVPC analysis suggests that the models can predict the distribution of observed tacrolimus concentrations for both immediate-and prolonged-release tacrolimus. The calculated median (based on 1000 simulated data sets) represented the trend of the observed data. There were 295 (1.3%) and 522 (2.3%) data points below and above the prediction intervals, respectively. Most observed concentrations were within the 95% prediction interval, indicating that the predicted variability did not exceed the observed variability. 
| Model simulation
| DISCUSSION
In this analysis, a 2-compartmental model with first-order elimination, first-order absorption, and an absorption lag time adequately described the PK of immediate-and prolonged-release tacrolimus in kidney, liver and heart transplant recipients. Prolonged-release tacrolimus had slower absorption than immediate-release tacrolimus, and clearance of tacrolimus was 59% higher in Asians than Whites. The PK of tacrolimus was similar between adult and paediatric populations in this study, and there was no effect of organ type; however, tacrolimus bioavailability differed between races. Interpatient variability in tacrolimus trough concentrations was similar for the immediate-and prolonged-release formulations. 
Residual variability was parameterized by the fixed-effect parameter (θ) for different assays.
b Eta-and epsilon-shrinkages were estimated only for covariates included in the final model. Interpatient variability and residual variability were expressed as %CV; %CV was expressed as 100 × (standard error of the estimate/point estimate). Median and 95% CI were estimated from non-parametric bootstrap estimates stratified by study.
ALAG1, absorption lag time; ALB, albumin; AST, aspartate aminotransferase; BOV, between-occasion variability; CI, confidence interval; CL, clearance; CL/ F, apparent oral clearance; CV, coefficient of variation; F1, relative bioavailability; IPV, interpatient variability; K a , absorption rate; Q, intercompartmental clearance; Q/F, intercompartmental oral clearance; RV, residual variability; V c , central volume of distribution; V p , peripheral volume of distribution; V c /F, apparent central volume of distribution; V p /F, apparent peripheral volume of distribution.
Typically, the estimated absorption rate of prolonged-release tacrolimus was 50% slower compared with immediate-release tacrolimus, due to the extended-release properties of the prolonged-release formulation. However, the absorption rate of prolonged-release tacrolimus showed similar variability (35.5%) to immediate-release tacrolimus. The absorption phase was similar across transplanted organ type, and between adult vs paediatric patients. During the first 6 weeks after transplantation, paediatric kidney transplant recipients require higher tacrolimus weight-normalized starting doses than adults.
34
Although 1 PK study of stable paediatric liver transplant recipients converted from immediate-to prolonged-release tacrolimus was included in this analysis, 27 there were only 17 paediatric patients in the study, compared with 391 adult patients. As such, there may be insufficient power to detect a significant age effect on principal PK parameters (CL, K a , V c , V p and F1). Tacrolimus V c was higher with increased vs lower concentrations of AST or ALB, which is consistent with tacrolimus usually being highly bound to plasma proteins, predominantly serum ALB. 4 Other confounders that could affect the level of bound tacrolimus include the haematocrit value. 35 The positive correlation between AST and V c and the negative correlation between AST and V p could be due to Blacks in order to achieve therapeutic concentrations has not been explicitly examined in clinical studies. In this study, the tacrolimus clearance was higher in Asians than in Whites, which could result in lower tacrolimus exposure-related trough concentrations in this population; however, it should be considered that the Asian population in this study was a heterogeneous group of Japanese, Chinese and Far East patients. Moreover, in a previous PK modelling study of tacrolimus in Asian liver transplant recipients, the estimated CL/F was 18.4 L/h, 36 which is lower than the clearance observed for Whites in our study (44.3 L/h). This indicates the need for further studies to confirm the dose requirements for Asian compared with White patients. 36 Lower relative bioavailability of tacrolimus in Blacks is consistent with earlier reports that African-Americans require higher doses of tacrolimus in order to achieve therapeutic drug concentrations. 37, 38 Tacrolimus is extensively metabolized by CYP3A4 and CYP3A5, with CYP3A5 polymorphism expressed at a higher frequency in African-Americans, 39 which could be responsible for the estimated racial effect. Presystemic metabolism by gastrointestinal CYP3A4
and P-glycoprotein (P-gp) has also been implicated in limiting oral bioavailability of tacrolimus. Conceivably, Blacks might express higher concentrations of P-gp in the gut and intestine, thereby decreasing tacrolimus bioavailability; 40 however, in the current study, CYP3A4 and P-gp variants were not included as covariates. In a retrospective study that formed part of the immediate-release tacrolimus development programme, simulated trough concentrations of tacrolimus were lower for Black vs White kidney transplant recipients, and
Blacks required higher immediate-release tacrolimus doses to attain similar trough tacrolimus concentrations to those in Whites. 41 Similar findings were reported for a subset of heart transplant patients There was no significant effect of sex on tacrolimus trough concentration; indeed a sex effect was only identified for V c in this study.
Tacrolimus trough concentrations increased with elevated This suggests that dose adjustments may be required for patients with hypoalbuminaemia.
It is not possible to explain why sex had an effect on volume of distribution, whereas weight did not. However, haematocrit and time after transplant are considered important covariates affecting tacrolimus PK, and a limitation of the study was the lack of inclusion of these covariates in the model. A further limitation was the observed high variability of the data and large size of the sample across different studies, which reduced the ability of the VPC for the model to predict the 5 th and 95 th percentiles.
In conclusion, the tacrolimus population PK model adequately described the tacrolimus PK data observed in transplant recipients. Of the assessed covariates, the PK of immediate-and prolonged-release tacrolimus was only affected by race, sex and liver function. The model confirmed that patients can be converted from immediate-release (Prograf) to prolonged-release (Advagraf or Astagraf XL) tacrolimus on a 1 mg:1 mg total-daily-dose basis, and showed that the population studied achieved clinical tacrolimus trough concentrations within the therapeutic range. However, for safety, it is important that following conversion from immediate-to prolonged-release tacrolimus, trough concentrations should be monitored and dose adjustments made to maintain exposure on an individual patient basis.
